Clinical efficacy of CLODRONIC ACID (cas 10596-23-3) in horses diagnosed with navicular syndrome: A field study using objective and subjective lameness evaluation

Add time:08/14/2019    Source:sciencedirect.com

Navicular syndrome, a common cause of equine forelimb lameness, is associated with pathological changes in the navicular bone. Consequently, administration of bisphosphonates (BPs) has been advocated in order to modify the rate of bone turnover. The present study aimed to assess the clinical efficacy of intramuscularly administered CLODRONIC ACID (cas 10596-23-3) for the treatment of 11 horses with clinical and radiographic findings compatible with navicular syndrome. Magnetic resonance imaging was performed in 5 of the 11 horses. The animals were treated with an intramuscular dose of clodronic acid of 765 mg/horse, administered over three separate injection sites. Before and at 7, 30 and 90 days after treatment, horses were subjected to lameness and accelerometric evaluations. A clinical improvement was observed in 6 of the 11 horses. These 6 horses showed a mean reduction of two degrees in lameness score. Accelerometry in these horses revealed increased velocity, stride length, stride regularity and dorsoventral displacement of the gravity of centre together with a reduction in stride frequency, suggesting a gait improvement. This study demonstrates that intramuscular clodronic acid can be useful for lameness reduction in some horses with navicular syndrome.

We also recommend Trading Suppliers and Manufacturers of CLODRONIC ACID (cas 10596-23-3). Pls Click Website Link as below: cas 10596-23-3 suppliers

Prev:Dose-response studies in carcinogenesis by nitroso-N-methyl-N-(2-phenyl)ethylamine in rats and the effects of deuterium substitution*
Next:Determination of impurities in CLODRONIC ACID (cas 10596-23-3) by anion-exchange chromatography)